Fred Ramsdell was on vacation in the Montana wilderness when he and two colleagues received the honor for their breakthroughs ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Clinical evidence from studies on atrial fibrillation (AF) and total knee arthroplasty (TKA) indicates that FXI is an appealing target that may upend the $15 billion thromboembolism market, which is ...

Marc Malone receives a 2025 Global Recognition Award for achieving the first functional reversal of gene silencing across ...

AstraZeneca will get exclusive rights to develop and sell approved therapies, if any, that target immune system-related ...

Germany’s soundproof trees, a world-first experiment that has captured the attention of urban planners, geneticists, and ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

A small S.F. biotech with ties to Nobel Prize-winning research has caught the attention of a pharmaceutical giant, resulting ...

CRISPR can edit DNA like text on a page — a tool powerful enough to cure disease or unleash chaos. Paired with AI, it could save millions… or become the deadliest weapon ever created ...

Social media never seems to run out of wellness tricks that promise big results in no time. From detox teas to apple cider vinegar shots, there’s always a new trend that claims to melt fat, flatten ...